FBLG

FibroBiologics Inc

1.49

Sep 17 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Sep 17, 8:35 AMFibroBiologics closes $0.5 million at-the-market private placement of stock and warrants with chief scientific officer

Peers: APRE GOVX KAPA BCDA BIVI KPRX LNAI CALC CVM NEUP

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	9.89M
Enterprise Value	7.83M
Income	-18.14M
Sales	0.00M
Book/sh	0.76
Cash/sh	0.53
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	15
IPO	Jan 31, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.95
P/C	2.81
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.64
Current Ratio	2.64
Debt/Eq	0.31
LT Debt/Eq	0.23
Option/Short	No / Yes

EPS (ttm)	-5.64
EPS next Y	-3.25
EPS next Q	-0.63
EPS this Y	64.29%
EPS next Y	-8.33%
EPS next 5Y	21.91%
EPS past 3/5Y	-38.37% -71.12%
Sales past 3/5Y	- -
EPS Y/Y TTM	22.10%
Sales Y/Y TTM	-
EPS Q/Q	72.78%
Sales Q/Q	-
Earnings	Jul 31 AMC
EPS/Sales Surpr.	29.03% -

Insider Own	12.24%
Insider Trans	0.00%
Inst Own	12.96%
Inst Trans	0.40%
ROA	-166.14%
ROE	-660.08%
ROIC	-317.34%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.85%
SMA50	27.71%
SMA200	-51.81%
Trades

Shs Outstand	6.08M
Shs Float	5.84M
Short Float	7.08%
Short Ratio	1.90
Short Interest	0.41M
52W High	12.40 -88.02%
52W Low	0.62 139.50%
Volatility	8.90% 12.44%
ATR (14)	0.17
RSI (14)	51.33
Beta	1.68
Rel Volume	0.00
Avg Volume	217.69K
Volume	0

Perf Week	-14.16%
Perf Month	30.26%
Perf Quarter	85.63%
Perf Half Y	-71.50%
Perf YTD	-66.99%
Perf Year	-85.87%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	6.00
Prev Close	1.49
Price	1.49
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-24	Initiated	Rodman & Renshaw	Buy	$12
Oct-30-24	Initiated	H.C. Wainwright	Buy	$12
Sep-24-24	Initiated	Maxim Group	Buy	$12

Sep-17-26 08:30AM	FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer (PR Newswire)
Sep-03-26 08:30AM	FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing (PR Newswire) -9.74%
Sep-01-26 08:30AM	FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media (PR Newswire) +22.67%
Aug-27-26 08:30AM	FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial (PR Newswire) +5.67%
04:25AM	FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia (Proactive)
08:30AM	Loading…
Aug-26-26 08:30AM	FibroBiologics Regains Compliance with Nasdaq Trading Rules (PR Newswire)
Aug-24-26 08:30AM	FibroBiologics Appoints Leigh Steinberg to Board of Directors (PR Newswire) -6.25%
Aug-20-26 08:30AM	FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease (PR Newswire) +8.40%
Aug-18-26 08:30AM	FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints (PR Newswire) +11.76%
Aug-11-26 08:30AM	FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets (PR Newswire) +5.10%
Aug-05-26 08:30AM	FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage (PR Newswire) +5.60%
Jul-31-26 05:34PM	FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate (PR Newswire) +12.93%
Jul-09-26 08:30AM	FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors (PR Newswire) +5.41%
Jul-07-26 08:30AM	FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial (PR Newswire)
Jun-30-26 08:30AM	FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference (PR Newswire) +19.22%
04:01PM	Loading…
Jun-29-26 04:01PM	FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire)
Jun-26-26 08:30AM	FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire) +12.67%
Jun-22-26 08:30AM	FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing (GlobeNewswire)
Jun-16-26 08:30AM	FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers (GlobeNewswire) -9.29%
Jun-03-26 07:00AM	FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers (GlobeNewswire)
May-22-26 08:30AM	FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting (GlobeNewswire)
May-18-26 08:30AM	FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics (GlobeNewswire)
May-11-26 08:30AM	FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus (GlobeNewswire) -14.66%
May-05-26 08:30AM	FibroBiologics CEO Issues Letter to Shareholders (GlobeNewswire)
May-04-26 04:01PM	FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring (GlobeNewswire) -5.48%
08:30AM	FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial (GlobeNewswire)
Apr-30-26 05:55PM	FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +10.61%
08:30AM	FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026 (GlobeNewswire)
Apr-20-26 04:01PM	FibroBiologics Compliant with All Nasdaq Listing Requirements (GlobeNewswire)
Apr-10-26 08:30AM	FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity (GlobeNewswire)
04:01PM	Loading…
Apr-02-26 04:01PM	FibroBiologics Announces Closing of $3 Million Public Offering (GlobeNewswire)
Mar-31-26 08:00PM	FibroBiologics Announces Pricing of $3 Million Public Offering (GlobeNewswire) -42.11%
04:15PM	FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial (GlobeNewswire)
Mar-25-26 04:30PM	FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement (GlobeNewswire) -16.51%
Mar-12-26 08:30AM	FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology (GlobeNewswire)
Mar-05-26 08:30AM	FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers (GlobeNewswire) +11.58%
Mar-03-26 10:02AM	Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them (PR Newswire) -7.22%
Mar-02-26 08:30AM	FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis (GlobeNewswire) +27.66%
Feb-26-26 08:30AM	FibroBiologics to Present at the BIO Investment & Growth Summit (GlobeNewswire) +7.44%
Feb-24-26 04:30PM	FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +5.73%
Feb-23-26 08:30AM	FibroBiologics Granted Extension by Nasdaq to Regain Compliance (GlobeNewswire)
Feb-10-26 08:30AM	FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University (GlobeNewswire) +6.24%
Feb-05-26 08:30AM	FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia (GlobeNewswire) -9.20%
Jan-20-26 08:30AM	FibroBiologics to Present at the DealFlow Discovery Conference (GlobeNewswire)
Jan-07-26 08:30AM	FibroBiologics CEO Issues Letter to Shareholders (GlobeNewswire) +32.27%
Jan-06-26 08:30AM	FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference (GlobeNewswire) +6.78%
Jan-05-26 08:30AM	FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease (GlobeNewswire)
Dec-31-25 08:30AM	FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis (GlobeNewswire) -7.03%
Dec-16-25 04:05PM	FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -8.44% +14.53%
Dec-15-25 08:00AM	FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -33.06%
Dec-10-25 08:30AM	FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions (GlobeNewswire) +12.82%
Nov-26-25 08:30AM	FibroBiologics Announces Payoff of Outstanding Debt (GlobeNewswire)
Nov-25-25 04:05PM	FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Nov-24-25 09:00AM	FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -23.53%
Nov-20-25 08:00AM	FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers (GlobeNewswire) -5.78%
Nov-19-25 07:03PM	FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
08:36AM	FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-31-25 04:30PM	FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-24-25 08:30AM	FibroBiologics to Present at Bio-Europe 2025 (GlobeNewswire) +6.28%
Oct-14-25 08:30AM	FibroBiologics to Present at the 2025 ThinkEquity Conference (GlobeNewswire)
Sep-23-25 08:30AM	FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-12-25 08:30AM	FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies (GlobeNewswire)
Sep-11-25 08:30AM	FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment (GlobeNewswire)
Sep-10-25 08:30AM	FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies (GlobeNewswire)
Aug-27-25 08:30AM	FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Jul-31-25 04:30PM	FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-28-25 08:30AM	FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications (GlobeNewswire)
Jul-11-25 08:30AM	FibroBiologics to Present at the Advanced Wound Care Summit USA (GlobeNewswire)
Jul-09-25 08:30AM	FibroBiologics Confirms Ability to Manufacture CybroCell for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank (GlobeNewswire) +9.04%
Jul-07-25 04:35PM	FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10 (GlobeNewswire)
Jun-16-25 04:35PM	FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing (GlobeNewswire) -5.48%
09:50AM	FibroBiologics to Present at the BIO International Convention 2025 (GlobeNewswire)
Jun-09-25 08:30AM	FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer (GlobeNewswire)
May-16-25 08:30AM	FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting (GlobeNewswire) -8.42%
May-14-25 04:30PM	FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +22.67%
Apr-29-25 09:15AM	FibroBiologics Presents at the ThymUS 2025 Meeting (GlobeNewswire) -8.37%
09:15AM	FibroBiologics Presenting at the ThymUS 2025 Meeting (GlobeNewswire)
Apr-11-25 08:30AM	FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean (GlobeNewswire) +9.50%
Apr-08-25 08:30AM	FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics (GlobeNewswire) -6.31%
Apr-02-25 08:30AM	FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair (GlobeNewswire) +8.88%
Mar-31-25 04:25PM	FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.26%
Mar-27-25 08:30AM	FibroBiologics Announces 2025 Annual Meeting of Stockholders (GlobeNewswire)
Mar-21-25 08:30AM	FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting (GlobeNewswire) +7.77%
Mar-14-25 08:35AM	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-12-25 01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
Mar-04-25 08:30AM	FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics (GlobeNewswire) +6.99%
Feb-27-25 08:30AM	FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic (GlobeNewswire)
Feb-05-25 09:15AM	FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates (GlobeNewswire) +6.45%
Dec-30-24 04:30PM	FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing (GlobeNewswire) -5.08% -10.71%
02:12PM	D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing (GlobeNewswire)
Dec-23-24 07:55AM	FibroBiologics Announces $25 Million Financing (GlobeNewswire) -6.67%
Nov-19-24 09:15AM	FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly (GlobeNewswire)
Nov-14-24 09:15AM	FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics (GlobeNewswire) -8.77%
Nov-12-24 04:20PM	FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.12%
Oct-29-24 09:15AM	FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology (GlobeNewswire)
Oct-28-24 09:31AM	FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024 (GlobeNewswire)
Oct-21-24 07:45AM	FibroBiologics and Charles River link for chronic disease therapies manufacture (Pharmaceutical Technology) -9.88%
Oct-18-24 08:30AM	FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases (GlobeNewswire)
Oct-16-24 09:15AM	FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office (GlobeNewswire) +17.82%
Oct-11-24 09:31AM	FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit (GlobeNewswire) +12.07%

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm's product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O'Heeron on April 8, 2021 and is headquartered in Houston, TX.

FounderMr. Peter O'Heeron

Chief Scientific OfficerDr. Hamid Khoja Ph.D.

General CounselMr. Ruben A. Garcia J.D.

Chief Financial OfficerMr. Jason D. Davis CPA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Khoja Hamid	Chief Scientific Officer	Mar 04 '26	Buy	0.38	30,000	11,400	61,250	Mar 05 08:00 AM
O'HEERON PETE	CHIEF EXECUTIVE OFFICER	Mar 03 '26	Buy	0.41	18,200	7,373	5,942,275	Mar 04 05:50 PM
O'HEERON PETE	CHIEF EXECUTIVE OFFICER	Mar 02 '26	Buy	0.35	17,428	6,152	5,924,075	Mar 04 05:50 PM
O'HEERON PETE	CHIEF EXECUTIVE OFFICER	Mar 04 '26	Buy	0.38	15,872	6,006	5,958,147	Mar 04 05:50 PM
Davis Jason	Chief Financial Officer	Mar 02 '26	Buy	0.41	70,000	28,973	70,000	Mar 03 08:00 AM
GARCIA RUBEN A	General Counsel	Feb 27 '26	Buy	0.33	40,000	13,056	180,000	Mar 02 09:15 AM
GARCIA RUBEN A	General Counsel	Dec 11 '25	Buy	0.34	140,000	47,600	140,000	Dec 12 07:16 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FBLG

FibroBiologics Inc

Upgrade your Finviz experience